A Randomized Study of the Effect of Maintenance Therapy With Bevacizumab + Capecitabine Versus Bevacizumab Alone on Progression-free Survival in Patients With HER2-negative Metastatic Breast Cancer That Has Not Progressed During First-line Docetaxel Plus Bevacizumab Therapy
2020-07-04
عنوان الدراسة
A Randomized Study of the Effect of Maintenance Therapy With Bevacizumab + Capecitabine Versus Bevacizumab Alone on Progression-free Survival in Patients With HER2-negative Metastatic Breast Cancer That Has Not Progressed During First-line Docetaxel Plus Bevacizumab Therapy
داعم الدراسة
Roche
دواء الدراسة
Bevacizumab+ Capecitabine
رقم بروتوكول الدراسة
MO22223
حالة الدراسة
Terminated
موقع الدراسة
King Abdulaziz Hospital and Oncology Center (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam)
مرحلة الدراسة
3
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.